These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 15165669)
21. Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization. Kuno-Sakai H; Kimura M Pediatr Int; 2004 Dec; 46(6):650-5. PubMed ID: 15660862 [TBL] [Abstract][Full Text] [Related]
22. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children. Vickers D; Ross AG; Mainar-Jaime RC; Neudorf C; Shah S CMAJ; 2006 Nov; 175(10):1213-7. PubMed ID: 17098950 [TBL] [Abstract][Full Text] [Related]
23. The epidemiology of fatalities reported to the vaccine adverse event reporting system 1990-1997. Silvers LE; Ellenberg SS; Wise RP; Varricchio FE; Mootrey GT; Salive ME Pharmacoepidemiol Drug Saf; 2001; 10(4):279-85. PubMed ID: 11760487 [TBL] [Abstract][Full Text] [Related]
24. A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis. Geier DA; Geier MR Med Sci Monit; 2005 Apr; 11(4):CR160-70. PubMed ID: 15795695 [TBL] [Abstract][Full Text] [Related]
25. Safety monitoring in vaccine development and immunization. Lee CJ; Lee LH; Lu CH; Huang YJ; Chu ML Acta Paediatr Taiwan; 2006; 47(1):7-13. PubMed ID: 17016963 [TBL] [Abstract][Full Text] [Related]
26. Overview of recent clinical trials of acellular pertussis vaccines. Miller E Biologicals; 1999 Jun; 27(2):79-86. PubMed ID: 10600188 [TBL] [Abstract][Full Text] [Related]
27. Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines. Gaines-Das R; Horiuchi Y; Zhang SM; Newland P; Kim Y; Corbel M; Xing D Vaccine; 2009 Nov; 27(49):6824-32. PubMed ID: 19765397 [TBL] [Abstract][Full Text] [Related]
28. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan. Kuno-Sakai H; Kimura M; Watanabe H Biologicals; 2004 Mar; 32(1):29-35. PubMed ID: 15026023 [TBL] [Abstract][Full Text] [Related]
29. Comparison of toxicities of acellular pertussis vaccine with whole cell pertussis vaccine in experimental animals. Sato Y; Sato H Dev Biol Stand; 1991; 73():251-62. PubMed ID: 1778317 [TBL] [Abstract][Full Text] [Related]
30. Development of acellular pertussis vaccines. Sato Y; Sato H Biologicals; 1999 Jun; 27(2):61-9. PubMed ID: 10600185 [TBL] [Abstract][Full Text] [Related]
31. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. America Academy of Pediatrics Commitee on Infectious Diseases Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131 [TBL] [Abstract][Full Text] [Related]
32. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life. Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348 [TBL] [Abstract][Full Text] [Related]
34. Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model. David S; van Furth R; Mooi FR Vaccine; 2004 May; 22(15-16):1892-8. PubMed ID: 15121300 [TBL] [Abstract][Full Text] [Related]
35. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985 [TBL] [Abstract][Full Text] [Related]
36. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Tapiainen T; Cherry JD; Heininger U Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771 [TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age. Nolan T; Bernstein H; Blatter MM; Bromberg K; Guerra F; Kennedy W; Pichichero M; Senders SD; Trofa A; Collard A; Sullivan DC; Descamps D Pediatrics; 2006 Sep; 118(3):e602-9. PubMed ID: 16950952 [TBL] [Abstract][Full Text] [Related]
38. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003. McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455 [TBL] [Abstract][Full Text] [Related]
39. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003. Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK; Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204 [TBL] [Abstract][Full Text] [Related]
40. Clinical implications of endotoxin concentrations in vaccines. Geier DA; Geier MR Ann Pharmacother; 2002 May; 36(5):776-80. PubMed ID: 11978151 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]